Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

ACINETWORK A training network for the design of synthetic carbohydrate-based vaccines in the fight against multi-drug resistant nosocomial pathogen Acinetobacter baumannii

Coordinator
Universita Degli Studi Di Milano, Italy
Runs
1 February 2024 to 31 January 2028
Status
Running
EU funding
€2.7m
Total cost
—
Partners
19 organisations in 7 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101119795

What the project is doing

In the project's own words, from its summary on CORDIS.

Bacterial infections are a societal burden with profound medical and socio-economic impacts. Although antibiotics can be effective, the continuous emergence of bacteria with antimicrobial resistance calls for the introduction of novel therapeutics. In this regard, glycoconjugate vaccines (GV) hold a prominent role in the fight against AMR bacterial strains. They are based on the chemical conjugation of one or more pathogen-associated saccharide antigens to immunogenic carriers, leading to a long-term protective immunity.

ACINETWORK will focus on the development of GV against severe and life-threatening infections caused by antimicrobial resistant Acinetobacter baumannii strains, which are a major cause of nosocomial diseases and for which no vaccine exists. ACINETWORK wants to overcome the limitations of currently licensed GV, due to highly heterogeneous composition and batch wise variability, by innovatively using structurally-defined synthetic oligosaccharide antigens to develop GV with well-defined composition, higher purity and better safety profiles.

The manufacturing of such GV is also more rapid and cost-effective. Thus, this project will set synthesis and testing pipelines that will serve as the prototype for the development of GV against other bacteria. The ACINETWORK consortium comprises universities and SMEs with a unique complementary expertise, ranging from carbohydrate chemistry to nanotechnology, immunology and microbiology, which garantees the realization of the new GV.

The goal of ACINETWORK is to also forge 10 young experts in the design of these novel medical solutions with an integrated training program, which will equip them with a large battery of scientific and transferable skills. The multidisciplinarity of the consortium ensures a fertile and stimulating environment in which these young researchers will acquire unique competencies in vaccine design, development and production, which will be central at putting Europe at the forefront of GV.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di MilanoMilanoItalyCoordinator
The Governors of the University of AlbertaEdmontonCanadaAssociatedpartner
European Molecular Biology LaboratoryHeidelbergGermanyAssociatedpartner
Freie Universitaet BerlinBerlinGermanyAssociatedpartner
Glycouniverse GmbH & Co. Kommanditgesellschaft Auf AktienPotsdamGermanyParticipant
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eVMunchenGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic BiomaguneSan SebastianSpainParticipant
Instituto De Salud Carlos IiiMadridSpainParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Universidad Nacional De Educacion a DistanciaMadridSpainAssociatedpartner
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Universite De MontpellierMontpellierFranceAssociatedpartner
Associazione Hand in HandNemiItalyAssociatedpartner
Consiglio Nazionale Delle RicercheRomaItalyAssociatedpartner
Fratagene Therapeutics srlRomeItalyAssociatedpartner
Idea75 SRLBariItalyAssociatedpartner
Universita Degli Studi Di FirenzeFlorenceItalyParticipant
Attana ABStockholmSwedenAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI